



Algorae Pharmaceuticals – Notice of AGM Proceedings

ASX: 1AI | 9 September 2026

Algorae Pharmaceuticals Limited (ASX: 1AI) ("Algorae" or "the Company") advises that, in accordance with ASX Listing Rule 3.13.1 and clause 17 of the Company's Constitution, the next Annual General Meeting ("AGM") of the Company is scheduled to be held at 11:00 am (AEST) on Thursday, 5 November 2026.

The closing date for the receipt of nominations from persons wishing to be considered for election as a director is 16 September 2026. Any nominations must be received in writing no later than 5:00pm (AEST) on 16 September 2026 at the Company's registered office.

Full details of the agenda for the AGM, including details of how shareholders can participate in the Meeting, will be contained in the Notice of AGM, which will also contain a proxy form. The Notice of AGM will be sent to shareholders and a copy released on the ASX Market Announcements Platform and on the Company's website in due course.

Authorised for release by the Board of Directors of Algorae Pharmaceuticals Ltd

END.

Corporate and Media Enquiries

Mr David Hainsworth

Executive Chairman

E: investors@algoraepharma.com

About Algorae Pharmaceuticals

Algorae Pharmaceuticals (ASX: 1AI) is an AI-enabled pharmaceutical company with a dual focus on drug-combination discovery and pharmaceutical commercialisation. The Company's proprietary AI platform, AlgoraeOS, applies machine learning and deep neural networks to identify synergistic drug combinations and guide dose selection for preclinical development. In parallel, Algorae operates a commercialisation business, AlgoraeRx, that sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels. Algorae collaborates with leading research institutions and industry partners to translate AI-predicted therapies and to expand patient access to high-quality medicines.

Algorae is listed and publicly traded on the Australian Securities Exchange (ASX: 1AI), providing investors an opportunity to participate in the Company's growth.

For more information visit www.algoraepharma.com or follow @algoraepharma on X or LinkedIn.